Myrobalan Therapeutics is a biotechnology company headquartered in Medford, Massachusetts, with a focus on developing oral neurorestorative therapies aimed at reversing key pathologies underlying brain dysfunctions and CNS conditions. Myrobalan applies deep knowledge of neurological processes such as demyelination and neuroinflammation, and innovative drug discovery tools, to create highly selective and brain-penetrant therapeutic candidates that are uniquely positioned for treating CNS conditions with significant unmet medical need. Myrobalan's rich pipeline of novel remyelination and anti-neuroinflammation programs are being advanced with the strategic support of renowned institutional co-founders and a leading chemistry partner.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/10/24 | $24,000,000 | Series A |
3E Bioventures AB Magnitude Ventures Group Co-win Ventures  Guan Zi Equity Investment | undisclosed |
